Development and evaluation of orally disintegrating tablets containing the mosapride resin complex
The purpose of this study was to prepare a mosapride citrate-resin (Amberlite® IRP 88) complex and orally fast-disintegrating tablets of the resin complex. The resinate complex of mosapride-Amberlite® IRP 88, mass ratio 2:1, was prepared in an ethanol-water solution. The effects of alcohol concentra...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Sciendo
2018-06-01
|
| Series: | Acta Pharmaceutica |
| Subjects: | |
| Online Access: | https://doi.org/10.2478/acph-2018-0017 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832574178276933632 |
|---|---|
| author | Wu Tong Wang Guanhua Shi Caihong Li Jinghan Zhao Na Dong Zihao Pan Weisan Zhang Xiangrong |
| author_facet | Wu Tong Wang Guanhua Shi Caihong Li Jinghan Zhao Na Dong Zihao Pan Weisan Zhang Xiangrong |
| author_sort | Wu Tong |
| collection | DOAJ |
| description | The purpose of this study was to prepare a mosapride citrate-resin (Amberlite® IRP 88) complex and orally fast-disintegrating tablets of the resin complex. The resinate complex of mosapride-Amberlite® IRP 88, mass ratio 2:1, was prepared in an ethanol-water solution. The effects of alcohol concentration, temperature, and pH of the solution on complex formation were evaluated. The complex physicochemical properties were characterized by differential scanning calorimetry, X-ray diffraction and scanning electron microscopy. Orally disintegrating tablets were prepared by direct compression and were optimized using the response surface method. Optimized orally fast-disintegrating tablets disintegrated within 18 s. The pH dependence of mosapride release from the tablet decreased drug dissolution in simulated saliva, whereas it promptly released in the pH 1.0 solution. The data reported herein clearly demonstrate that tablets containing the mosapride-Amberlite® IRP 88 complex for oral disintegration could be particularly useful for patients with swallowing difficulties. |
| format | Article |
| id | doaj-art-9c0240a1c18e48119ab117c7c2ac10a9 |
| institution | Kabale University |
| issn | 1846-9558 |
| language | English |
| publishDate | 2018-06-01 |
| publisher | Sciendo |
| record_format | Article |
| series | Acta Pharmaceutica |
| spelling | doaj-art-9c0240a1c18e48119ab117c7c2ac10a92025-02-02T00:32:27ZengSciendoActa Pharmaceutica1846-95582018-06-0168215917010.2478/acph-2018-0017acph-2018-0017Development and evaluation of orally disintegrating tablets containing the mosapride resin complexWu Tong0Wang Guanhua1Shi Caihong2Li Jinghan3Zhao Na4Dong Zihao5Pan Weisan6Zhang Xiangrong7School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang110016, P.R. ChinaSchool of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang110016, P.R. ChinaSchool of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang110016, P.R. ChinaSchool of Pharmacy, Shenyang Pharmaceutical University, Shenyang110016, Liaoning Province, P.R. ChinaSchool of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang110016, P.R. ChinaSchool of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang110016, P.R. ChinaSchool of Pharmacy, Shenyang Pharmaceutical University, Shenyang110016, Liaoning Province, P.R. ChinaSchool of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang110016, P.R. ChinaThe purpose of this study was to prepare a mosapride citrate-resin (Amberlite® IRP 88) complex and orally fast-disintegrating tablets of the resin complex. The resinate complex of mosapride-Amberlite® IRP 88, mass ratio 2:1, was prepared in an ethanol-water solution. The effects of alcohol concentration, temperature, and pH of the solution on complex formation were evaluated. The complex physicochemical properties were characterized by differential scanning calorimetry, X-ray diffraction and scanning electron microscopy. Orally disintegrating tablets were prepared by direct compression and were optimized using the response surface method. Optimized orally fast-disintegrating tablets disintegrated within 18 s. The pH dependence of mosapride release from the tablet decreased drug dissolution in simulated saliva, whereas it promptly released in the pH 1.0 solution. The data reported herein clearly demonstrate that tablets containing the mosapride-Amberlite® IRP 88 complex for oral disintegration could be particularly useful for patients with swallowing difficulties.https://doi.org/10.2478/acph-2018-0017mosapride citrateamberlite® irp 88 resinresin complexorally disintegrating tabletphysicochemical characterizationdissolution |
| spellingShingle | Wu Tong Wang Guanhua Shi Caihong Li Jinghan Zhao Na Dong Zihao Pan Weisan Zhang Xiangrong Development and evaluation of orally disintegrating tablets containing the mosapride resin complex Acta Pharmaceutica mosapride citrate amberlite® irp 88 resin resin complex orally disintegrating tablet physicochemical characterization dissolution |
| title | Development and evaluation of orally disintegrating tablets containing the mosapride resin complex |
| title_full | Development and evaluation of orally disintegrating tablets containing the mosapride resin complex |
| title_fullStr | Development and evaluation of orally disintegrating tablets containing the mosapride resin complex |
| title_full_unstemmed | Development and evaluation of orally disintegrating tablets containing the mosapride resin complex |
| title_short | Development and evaluation of orally disintegrating tablets containing the mosapride resin complex |
| title_sort | development and evaluation of orally disintegrating tablets containing the mosapride resin complex |
| topic | mosapride citrate amberlite® irp 88 resin resin complex orally disintegrating tablet physicochemical characterization dissolution |
| url | https://doi.org/10.2478/acph-2018-0017 |
| work_keys_str_mv | AT wutong developmentandevaluationoforallydisintegratingtabletscontainingthemosaprideresincomplex AT wangguanhua developmentandevaluationoforallydisintegratingtabletscontainingthemosaprideresincomplex AT shicaihong developmentandevaluationoforallydisintegratingtabletscontainingthemosaprideresincomplex AT lijinghan developmentandevaluationoforallydisintegratingtabletscontainingthemosaprideresincomplex AT zhaona developmentandevaluationoforallydisintegratingtabletscontainingthemosaprideresincomplex AT dongzihao developmentandevaluationoforallydisintegratingtabletscontainingthemosaprideresincomplex AT panweisan developmentandevaluationoforallydisintegratingtabletscontainingthemosaprideresincomplex AT zhangxiangrong developmentandevaluationoforallydisintegratingtabletscontainingthemosaprideresincomplex |